A beneficial deal
31/08/24 -"We have integrated the recent figures, which were broadly in line with our expectations. The positive from the out-licencing of the most advanced pipeline assets (all the mRNA vaccine candidates ..."
Pages
55
Language
English
Published on
31/08/24
You may also be interested by these reports :
13/11/25
The Q3 results exceeded the street’s expectations, driven by healthy top-line growth across all segments and a profitability beat (also aided by a ...
12/11/25
The Q3 profitability beat was driven by Crop Science, though Pharmaceuticals witnessed lower operating profits. Also, the management maintained its ...
10/11/25
The US government has agreed with Novo and Lilly to lower their weight-loss drugs’ prices, mainly in return for a three-year tariff exemption and ...
07/11/25
Genmab’s Q3 results surpassed the street’s expectations, driven by robust performance across most offerings, resulting in solid profitability ...